AbbVie Inc.

83.92-0.4200-0.50%Vol 7.67M1Y Perf 8.82%
Oct 26th, 2020 16:02 DELAYED
BID83.71 ASK83.90
Open84.09 Previous Close84.34
Pre-Market- After-Market84.00
 - -%  0.08 0.10%
Target Price
108.64 
Analyst Rating
Moderate Buy 1.64
Potential %
29.46 
Finscreener Ranking
★★★     50.28
Insiders Trans % 3/6/12 mo.
-/-100/11 
Value Ranking
★★★+     54.67
Insiders Value % 3/6/12 mo.
-/-100/-87 
Growth Ranking
★★★+     56.61
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-84 
Income Ranking
★★★     51.33
Market Cap148.10B 
Earnings Rating
Buy
Price Range Ratio 52W %
55.18 
Earnings Date
30th Oct 2020

Today's Price Range

82.8184.32

52W Range

62.55101.28

5 Year PE Ratio Range

16.3065.10

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-0.39%
1 Month
-2.68%
3 Months
-12.90%
6 Months
-0.91%
1 Year
8.82%
3 Years
-8.71%
5 Years
61.28%
10 Years
-

TickerPriceChg.Chg.%
ABBV83.92-0.4200-0.50
AAPL115.050.01000.01
GOOG1 590.45-50.5500-3.08
MSFT210.08-6.1500-2.84
XOM33.35-0.8100-2.37
WFC22.70-0.5800-2.49
JNJ143.97-1.2700-0.87
FB277.11-7.6800-2.70
GE7.38-0.2500-3.28
JPM101.24-2.5700-2.48
Financial StrengthValueIndustryS&P 500US Markets
0.60
0.90
0.85
5.94
4.30
Leverage Ratio 36.30
ProfitabilityValueIndustryS&P 500US Markets
73.60
26.80
35.40
25.70
18.22
RevenueValueIndustryS&P 500US Markets
27.75B
15.72
3.08
7.36
DividendsValueIndustryS&P 500US Markets
5.60
4.72
20.81
18.95
Payout ratio77.00
Earnings HistoryEstimateReportedSurprise %
Q02 20202.242.344.46
Q01 20202.272.426.61
Q04 20192.202.210.45
Q03 20192.292.331.75
Q02 20192.212.262.26
Q01 20192.062.143.88
Q04 20181.921.90-1.04
Q03 20182.012.146.47
Earnings Per EndEstimateRevision %Trend
9/2020 QR2.750.00-
12/2020 QR2.92-1.35Negative
12/2020 FY10.42-0.29Negative
12/2021 FY12.13-0.25Negative
Next Report Date30th Oct 2020
Estimated EPS Next Report2.75
Estimates Count6
EPS Growth Next 5 Years %5.80
Volume Overview
Volume7.67M
Shares Outstanding1.76B
Trades Count76.30K
Dollar Volume682.66M
Avg. Volume9.65M
Avg. Weekly Volume7.09M
Avg. Monthly Volume6.93M
Avg. Quarterly Volume7.15M

AbbVie Inc. (NYSE: ABBV) stock closed at 83.92 per share at the end of the most recent trading day (a -0.5% change compared to the prior day closing price) with a volume of 7.99M shares and market capitalization of 148.10B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 30000 people. AbbVie Inc. CEO is Richard A. Gonzalez.

The one-year performance of AbbVie Inc. stock is 8.82%, while year-to-date (YTD) performance is -5.22%. ABBV stock has a five-year performance of 61.28%. Its 52-week range is between 62.55 and 101.28, which gives ABBV stock a 52-week price range ratio of 55.18%

AbbVie Inc. currently has a PE ratio of 18.00, a price-to-book (PB) ratio of 10.12, a price-to-sale (PS) ratio of 5.36, a price to cashflow ratio of 8.70, a PEG ratio of 2.32, a ROA of 6.71%, a ROC of 13.28% and a ROE of 220.71%. The company’s profit margin is 18.22%, its EBITDA margin is 35.40%, and its revenue ttm is $27.75 Billion , which makes it $15.72 revenue per share.

Of the last four earnings reports from AbbVie Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.75 for the next earnings report. AbbVie Inc.’s next earnings report date is 30th Oct 2020.

The consensus rating of Wall Street analysts for AbbVie Inc. is Moderate Buy (1.64), with a target price of $108.64, which is +29.46% compared to the current price. The earnings rating for AbbVie Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AbbVie Inc. has a dividend yield of 5.60% with a dividend per share of $4.72 and a payout ratio of 77.00%.

AbbVie Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.29, ATR14 : 1.69, CCI20 : -125.19, Chaikin Money Flow : -0.20, MACD : -1.51, Money Flow Index : 40.36, ROC : -4.31, RSI : 38.08, STOCH (14,3) : 21.79, STOCH RSI : 0.59, UO : 41.92, Williams %R : -78.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AbbVie Inc. in the last 12-months were: Brian L. Durkin (Buy at a value of $362 705), Carlos Alban (Sold 53 325 shares of value $5 332 554 ), Edward J. Rapp (Buy at a value of $252 617), Jeffrey Ryan Stewart (Sold 23 024 shares of value $2 072 210 ), Timothy J. Richmond (Sold 19 445 shares of value $1 652 825 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (64.29 %)
8 (66.67 %)
6 (50.00 %)
Moderate Buy
1 (7.14 %)
1 (8.33 %)
0 (0.00 %)
Hold
4 (28.57 %)
3 (25.00 %)
6 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.64
Moderate Buy
1.58
Moderate Buy
2.00

AbbVie Inc.

AbbVie is a drug company with a strong exposure to immunology and oncology. The company's top drug, Humira, represents over half of the company's current profits. The company was spun off from Abbott in early 2013. The recent announced acquisition of Allergan will add several new drugs in aesthetics and women's health.

CEO: Richard A. Gonzalez

Teplephone: +1 847 932-7900

Address: 1 North Waukegan Road, North Chicago 60064-6400, IL, USA

Number of employees: 30 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

55%45%

Bearish Bullish

35%65%

Bearish Bullish

44%56%

News

Stocktwits